ImmuneWalk Therapeutics
Sector: Healthcare & Life Sciences
About ImmuneWalk Therapeutics
ImmuneWalk Therapeutics ImmuneWalk Therapeutics ImmuneWalk Therapeutics ImmuneWalk Therapeutics ImmuneWalk Therapeutics Home New Biology Our Technology Clinical Program Market Potential News & Events More Home New Biology Our Technology Clinical Program Market Potential News & Events ImmuneWalk Therapeutics ImmuneWalk Therapeutics ImmuneWalk Therapeutics ImmuneWalk Therapeutics Home New Biology Ou
Products
IW-601
A monoclonal antibody that prevents monocytes & neutrophils from entering inflamed tissues IW-601 is an antibody that specifically targets MOSPD2, a newly discovered adhesion checkpoint on the surface of myeloid cells (more specifically on monocytes and neutrophils). nhibition of MOSPD2 locks these immune cells in a sticky state by activating β2-integrin (an adhesion protein) thereby preventing their entrance into inflammatory tissues and reducing the propagation of immune responses. IW-601’s novel mechanism offers potential advantages over traditional approaches by overcoming the redundancy of chemotaxis pathways and directly modulating tissue inflammation without depleting immune cells.